glp-1 drugs and pancreatitis Frontiers GLP-1 Agonists and Pancreatitis Risk
Description
Michael Futter was desperate to lose weight
A study published in Diabetes Obes Metab showed that semaglutide resulted in over a decade of greater reduction of body weight than placebo, lifestyle modification or pharmacotherapy with orlistat after 68 weeks of treatment
This supports weight management goals, but it also means many users eat significantly less food than before
In collaboration with Reuters, Truveta Research explored trends in FDA-approved anti-obesity GLP-1 RA prescriptions among adolescents
The order got nowhere before former President Joe Biden took office and promptly repealed it
A challenge during the early development of GLP-1-based therapy was its short half-life in the circulation (approximately 2 min after i.v
